Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance.

For lower LAG3 expression (dichotomized by median expression) in primary tumors there was a trend towards better OS and PFS using the first immunotherapy treatment as the starting timepoint, although this did not reach statistical significance ( Figure 4C ).

also in 111,027 other papers

LAG3 expression in metastases was similarly not significantly associated with OS and PFS, although there was a weak trend towards better OS in patients with higher LAG3 ( Figure 4D ).

also in 1,404 other papers